Can Your Genes Make You More Vulnerable to Addiction?

When we talk about addiction, it is easy to think of it as a matter of choice, behaviour or willpower. However, decades of research have revealed that the reality is far more complex.

Genetics play a role in how susceptible someone may be to developing a substance use disorder (SUD), but they are not the only factor. Stress, environment, mental health, social circumstances and exposure to addictive substances all contribute to this complex picture.

Being genetically predisposed does not mean someone is destined to develop an addiction. There is no single "addiction gene," and having a genetic vulnerability does not determine an individual's future. Instead, researchers have found that many genetic variations can contribute to addiction risk, often through small individual effects that interact with environmental influences.

Recognizing this distinction is important because it changes how we understand addiction. Rather than viewing it simply as a failure of self-control, research increasingly identifies it as a complex health condition shaped by interactions between biology, behaviour and environment.

There Is No Single "Addiction Gene"

In the early stages of addiction research, scientists often focused on specific genes associated with neurotransmitters such as dopamine or the body's response to certain substances. While some of these genes have been linked to addiction-related traits, modern research suggests that the underlying biology is much more complex.

Substance use disorders are considered polygenic conditions, meaning that many genetic variants can influence susceptibility rather than a single gene determining whether someone develops an addiction. Although most individual variants have relatively small effects, their combined influence can contribute to differences in vulnerability between individuals.

Genes can affect several biological processes associated with addiction, including how the brain responds to rewards, how neurotransmitters function, how substances are metabolized, and how neural circuits develop and adapt.

Some genetic influences also overlap across different substance use disorders. This may help explain why genetic vulnerability to one substance use disorder can be associated with increased susceptibility to others, although the relationship is not identical across all substances.

What Have Large Genetic Studies Found?

Modern genome-wide association studies (GWAS) allow researchers to examine millions of genetic variants across large groups of people. Rather than focusing on individual genes suspected of influencing addiction, these studies scan the genome for variants that appear more frequently among people with particular traits or conditions.

A study published in Molecular Psychiatry examined genetic data associated with alcohol, cannabis, opioid and tobacco use disorders across populations with European, African and admixed American genetic ancestries. Researchers identified genetic signals shared across multiple substance use disorders, supporting the idea that different forms of addiction may have some underlying biological vulnerabilities in common.

Other large-scale genetic studies have identified both shared and substance-specific genetic associations. For example, research involving more than one million participants has identified genetic regions associated with vulnerability across several substance use disorders, alongside variants more strongly associated with particular substances.

These findings are important because they move addiction research beyond identifying whether a particular genetic variant is associated with substance use. Researchers can also investigate how these variants influence biological processes, how they affect brain function and whether the pathways involved could eventually inform new treatments.

So, Can a Genetic Test Tell Who Will Become Addicted?

Not at this time.

Researchers can calculate what is known as a polygenic risk score, which combines information from multiple genetic variants to estimate an individual's inherited statistical susceptibility to a particular condition.

However, a polygenic risk score cannot reliably predict whether a specific person will develop a substance use disorder.

Someone may carry genetic variants associated with increased vulnerability and never develop an addiction. Conversely, another person may have a lower estimated genetic risk but still develop a substance use disorder.

This illustrates why genetics must be considered alongside other influences.

Stress, trauma, family circumstances, access to substances, socioeconomic conditions, mental health, peer influences and the age at which someone first uses a substance can all affect vulnerability. Research increasingly demonstrates that genetic and environmental factors interact rather than operate independently.

There is also an important limitation in how genetic risk is currently measured. Many large genetic studies have historically included a disproportionate number of participants of European ancestry. As a result, genetic risk estimates developed using these datasets may be less accurate when applied to people from other ancestral backgrounds.

More recent studies have begun including more diverse populations, although gaps in representation remain.

For these reasons, genetic information should not be used to label someone as a person who will inevitably develop an addiction. Genetic susceptibility represents a potential risk, not a predetermined outcome.

What Makes Some People More Vulnerable to Addiction?

One reason researchers are investigating the genetics of addiction is that genetic differences can influence biological systems involved in reward, motivation, learning, stress and behavioural regulation.

These systems do not operate independently. They interact within networks of brain circuits that can change in response to experiences and environmental influences.

Repeated exposure to addictive substances can produce lasting changes in brain function and the regulation of gene activity. In a 2025 review, neuroscientist Eric Nestler examined how advances in genetics and neuroscience have improved researchers' understanding of the molecular, cellular and neural changes associated with addiction.

These findings help explain why addiction cannot be reduced to someone repeatedly making the wrong choice. Repeated substance use can alter biological processes involved in craving, motivation and reward, making patterns of substance use increasingly difficult to control.

Genetic differences may also influence how individuals respond to these experiences, although they do not determine the outcome on their own.

Addiction vulnerability is therefore better understood as an interaction between several factors: genetic vulnerability, environmental influences, substance exposure and changes in brain function. Rather than one straightforward cause, these factors can interact over time to influence whether a person develops a substance use disorder.

Could These Genetic Discoveries Lead to Better Treatments?

Identifying genetic associations is only the beginning. Researchers are increasingly interested in understanding which biological pathways are involved in addiction and whether changes to those pathways could improve treatment.

A 2024 review published in Molecular Psychiatry examined how genetic studies can be combined with information about gene expression, biological pathways and clinical outcomes. This approach may help researchers identify potential treatment targets and better understand why individuals respond differently to existing medications.

These developments have also encouraged interest in precision medicine for substance use disorders.

Precision medicine aims to use information about an individual's biological characteristics, health history and other relevant factors to guide treatment decisions. In addiction research, scientists are investigating whether genetic, neuroimaging, behavioural and environmental information could eventually help explain differences in treatment response.

Pharmacogenetic research examines how genetic variation influences responses to medications, while epigenetic research investigates changes in gene regulation that do not alter the underlying DNA sequence.

Both areas may eventually contribute to more individualized approaches to addiction treatment. However, substantial research is still needed before genetic risk information can be routinely used to guide clinical decisions for substance use disorders.

In simpler terms, researchers are gradually expanding their focus from asking: "Which genes are linked to addiction?" To asking: "What biological processes do these genes influence, and could understanding those processes help us develop better treatments?"

From Genes to Potential Targets

Translating genetic discoveries into effective treatments is a complex process.

Just because a gene is associated with addiction does not mean it can be directly targeted by a medication. Researchers must first determine whether the association reflects a biological mechanism involved in the condition, understand how that mechanism functions and establish whether modifying it could be both effective and safe.

Experimental studies are investigating these questions at the level of genes, cells and neural circuits. Although many of these approaches remain in the early stages of research, they offer potential directions for developing more targeted interventions.

Researchers are also exploring whether existing medications could be repurposed to influence biological pathways associated with substance use disorders.

Rather than developing an entirely new medication, this approach involves investigating whether a drug already used for another condition might affect a pathway relevant to addiction.

Genetic research can help identify potential candidates for further investigation, but laboratory findings and statistical associations do not automatically establish that a medication will be effective in patients. Clinical testing remains necessary to determine safety and effectiveness.

Ultimately, the goal of addiction genetics is not to predict someone's future or reduce addiction to their DNA. It is to better understand why vulnerability differs between individuals and how that knowledge might improve prevention, treatment and recovery support.

The growing evidence reinforces an important distinction: genes can influence addiction risk, but they do not determine a person's outcome. Understanding the interaction between genetics, environment and experience may help researchers develop more effective approaches to care while challenging the misconception that addiction is simply a failure of willpower.